Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02705677 · ClinicalTrials.gov registry record
Biobanking of Rett Syndrome and Related Disorders
A clinical trial, sponsored by University of Alabama at Birmingham.
- Completed
- Registry status
- 752
- Enrollment target
NCT02705677 is a clinical trial that has completed, run by University of Alabama at Birmingham. The registered enrollment target is 752 participants.
The verdict
NCT02705677 has completed, sponsored by University of Alabama at Birmingham.
- COMPLETED
- Registry status
- 752 participants
- Enrollment target
Study Summary
The overarching purpose of this study is to advance understanding of the natural history of Rett syndrome (RTT), MECP2-duplication disorder (MECP2 Dup), RTT-related disorders including CDKL5, FOXG1, and individuals with MECP2 mutations who do not have RTT. Although all these disorders are the result of specific genetic changes, there remains broad clinical variation that is not entirely accounted for by known biological factors. Additionally, clinical investigators currently do not have any biomarkers of disease status, clinical severity, or responsiveness to therapeutic intervention. To address these issues, biological materials (DNA, RNA, plasma, cell lines) will be collected from affected individuals and in some cases from unaffected family members, initial evaluation performed to identify additional biological factors contributing to disease severity, and these materials will be stored for future characterization.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 752 participants |
| Start Date | 2017-09-01 |
| Est. Completion | 2021-07-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02705677
The ClinicalTrials.gov registry entry for NCT02705677 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 752 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Alabama at Birmingham, which has 1,160 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT02705677 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02705677 about?
NCT02705677 is a clinical study titled "Biobanking of Rett Syndrome and Related Disorders". The overarching purpose of this study is to advance understanding of the natural history of Rett syndrome (RTT), MECP2-duplication disorder (MECP2 Dup), RTT-related disorders including CDKL5, FOXG1, and individuals with MECP2 mutations who do not have RTT. Although all these disorders are the result...
What is the current status of trial NCT02705677?
This trial is currently completed. The enrollment target is 752 participants. The study started on 2017-09-01. Estimated completion is 2021-07-31.
Who is sponsoring clinical trial NCT02705677?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.